;
Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of : Financial News

 Current Issue
  • FINANCIAL NEWS: Angion withdraws IPO

    Angion Biomedica Corp. (Uniondale, N.Y.) withdrew its proposed IPO on NASDAQ, citing market conditions. In June, the company amended its IPO to sell 2.7 million shares at $10-$12. At $11, the company would have raised $…

    Published on 10/24/2014
  • FINANCIAL NEWS: Coherus sets IPO terms

    Biosimilars developer Coherus Biosciences Inc. (Redwood City, Calif.) set terms for its IPO on NASDAQ and plans to sell 6.3 million shares at $12-$15. At $13.50 Coherus would raise $85 million and be valued at $432.7 …

    Published on 10/24/2014
  • FINANCIAL NEWS: Alexion, BioMarin raise 2014 guidance

    Rare disease specialists Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) both raised 2014 guidance in earnings reports on Thursday.Alexion shares added $12.65 to $185.92 after …

    Published on 10/23/2014
  • FINANCIAL NEWS: Erytech raises EUR 30M in follow-on

    Erytech Pharma S.A. (Euronext:ERYP) raised EUR 30 million ($38.2 million) through the sale of 1.2 million shares at EUR 24.50 in a follow-on. U.S. investors provided 68% of the funds.Erytech will use the money to …

    Published on 10/23/2014
  • FINANCIAL NEWS: Probiodrug raises EUR 22.5M in IPO

    Probiodrug AG (Euronext:PBD) raised EUR 22.5 million ($28.7 million) in an IPO through the sale of 1.5 million shares at EUR 15.25 on Euronext Amsterdam, giving the company a market cap of EUR 102.4 million ($130.6 …

    Published on 10/23/2014
  • FINANCIAL NEWS: Quartet raises $17M series A

    Analgesic developer Quartet Medicine (Cambridge, Mass.) raised $17 million in a series A round led by Atlas Venture. Novartis Venture Funds, Pfizer Venture Investment and Partners Innovation Fund also participated. …

    Published on 10/23/2014
  • FINANCIAL NEWS: S1 Biopharma sets IPO range

    S1 Biopharma Inc. (New York, N.Y.) amended its IPO on NASDAQ and plans to sell 2.8 million shares at $12-$14. At $13, the company would raise $35.8 million and be valued at $118.6 million. S1 Biopharma filed to raise up…

    Published on 10/23/2014
  • FINANCIAL NEWS: DBV Technologies launches ADSs

    American Depository Receipts for DBV Technologies S.A. (NASDAQ:DBVT; Euronext:DBV) added $1.26 to $22.90 on NASDAQ Wednesday after the allergy company sold 4.3 million ADSs at $21.64 each in a follow-on that, combined …

    Published on 10/22/2014
  • FINANCIAL NEWS: Forendo closes EUR 12M series A

    Forendo Pharma Oy (Turku, Finland) closed a EUR 12 million ($15.3 million) series A round led by new investors Novartis Venture Fund and MS Ventures. Existing investors including Karolinska Development AB; Novo Seeds; …

    Published on 10/22/2014
  • FINANCIAL NEWS: Molecular Partners postpones big Swiss IPO

    Ophthalmic and cancer company Molecular Partners AG (Schlieren, Switzerland) postponed plans for a big IPO on the SIX Swiss Exchange, citing "adverse market conditions." The company had begun bookbuilding on Oct. 8 and …

    Published on 10/22/2014
  • FINANCIAL NEWS: Proteon raises $61.1M in IPO

    Proteon Therapeutics Inc. (NASDAQ:PRTO) closed up $0.03 to $10.03 in its first day of trading Wednesday after raising $61.1 million by selling 6.1 million shares at $10 in an IPO on NASDAQ. The price valued Proteon at $…

    Published on 10/22/2014
  • FINANCIAL NEWS: Illumina, Actelion boost guidance

    Illumina Inc. (NASDAQ:ILMN) gained $2.1 billion in market cap on Tuesday in the wake of its earnings release after market on Monday. The shares added $15.08 to $179.55 after the sequencing company said revenue jumped 35…

    Published on 10/21/2014
  • FINANCIAL NEWS: Tobira amends IPO

    Tobira Therapeutics Inc. (San Francisco, Calif.) amended the terms for its proposed IPO on NASDAQ underwritten by Oppenheimer & Co., removing the price range, the number of shares and several of the underwriters. The …

    Published on 10/21/2014
  • FINANCIAL NEWS: Unum launches with $12M series A

    Oncology play Unum Therapeutics Inc. (Cambridge, Mass.) raised $12 million in a series A round led by Atlas Venture and Fidelity Biosciences. Sanofi-Genzyme BioVentures also participated.Unum uses its antibody-coupled T…

    Published on 10/21/2014
  • FINANCIAL NEWS: Viamet replaces IPO with $60M D round

    One day after withdrawing a proposed IPO, Viamet Pharmaceuticals Inc. (Durham, N.C.) closed a $60 million series D round led by new investor Brandon Point Industries Ltd. working with Woodford Investment Management. The…

    Published on 10/21/2014
  • FINANCIAL NEWS: DBV sets terms for dual listing

    DBV Technologies (Euronext:DBV) finalized the details of its planned global offering of shares that will include a dual-listing of ADSs on NASDAQ. The allergy specialist now plans to sell up to 2.7 million ordinary …

    Published on 10/20/2014
  • FINANCIAL NEWS: HealthCare Royalty Partners closes $1.5B fund

    HealthCare Royalty Partners closed its third fund, HealthCare Royalty Partners III, at $1.5 billion, which the firm said exceeded its original target by over 75%. Managing Director Todd Davis told BioCentury the firm …

    Published on 10/20/2014
  • FINANCIAL NEWS: PureTech raises $55M

    Science and technology development firm PureTech Ventures (Boston, Mass.) raised $55 million from Invesco Perpetual and other investors including endowments, angels and pharma companies. The funding builds on about $32…

    Published on 10/20/2014
  • FINANCIAL NEWS: Viamet withdraws IPO

    Viamet Pharmaceuticals Inc. (Durham, N.C.) withdrew its proposed IPO on NASDAQ. The company did not provide a reason in its SEC filing and did not respond to inquiries. In July, the infectious disease play filed to …

    Published on 10/20/2014
  • FINANCIAL NEWS: Neothetics, PolyPid file for IPOs

    Neothetics Inc. (San Diego, Calif.) and PolyPid Ltd. (Petach Tikva, Israel) filed for IPOs on NASDAQ. Neothetics filed to raise up to $63.3 million with Piper Jaffray; Guggenheim Securities; and Needham as underwriters…

    Published on 10/17/2014
  • FINANCIAL NEWS: Tetraphase prices $75M follow-on

    Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) climbed $4 (20%) to $24.11 on Friday after announcing it has priced the sale of 3.95 million shares at $19 in a follow-on that is expected to close Oct. 22. The company …

    Published on 10/17/2014
  • FINANCIAL NEWS: Atara raises $55M in IPO

    Atara Biotherapeutics Inc. (NASDAQ:ATRA) was down $0.35 to $10.65 in its first day of trading Thursday after it raised $55 million through the sale of 5 million shares at $11 in an IPO. The price valued Atara at $213.4 …

    Published on 10/16/2014
  • FINANCIAL NEWS: Dance withdraws IPO

    Dance Biopharm Inc. (Brisbane, Calif.) withdrew its proposed IPO on NASDAQ. The diabetes company did not provide a reason in its SEC filing. In April, the company filed to raise up to $75 million in a deal …

    Published on 10/16/2014
  • FINANCIAL NEWS: Esperion haircut after $85M follow-on

    Esperion Therapeutics Inc. (NASDAQ:ESPR) lost $2.56 (11%) to $20.69 after it raised $85 million through the sale of 4.3 million shares at $20 in a follow-on underwritten by J.P. Morgan; BofA Merrill Lynch; JMP …

    Published on 10/16/2014
  • FINANCIAL NEWS: Forward Pharma raises $220.5M in IPO

    Forward Pharma A/S (NASDAQ:FWP) fell $3.50 (17%) to $17.50 in its first day of trading on Wednesday after it raised $220.5 million through the sale of 10.5 million American Depositary Shares (ADSs) at $21 in an IPO. …

    Published on 10/15/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993